Swiss pharma giant navigating high-stakes drug landscape
Swiss voters have rejected the Swiss People’s Party initiative to cap the country’s population at 10 million by 2050, with roughly 55% voting against and 45% in favour. The measure would have forced stricter asylum and family-reunification rules once population hit 9.5 million and could have ended free movement with the EU if the 10 million limit were breached.
GSK has struck a multi-billion deal to acquire Nuvalent, adding three late-stage cancer drugs to its portfolio, including two lung-cancer therapies under FDA review. The acquisition aims to boost sales growth, expand the lung-cancer platform, and position GSK for a potential rise in annual revenue by 2031.
Recent reporting shows chronic inflammation is linked to aging disorders such as cancer and Alzheimer’s. Studies indicate inflammation may be a cause, not just a symptom, of broad health risks. Policy and lifestyle factors are under scrutiny as researchers push for preventative strategies.
Eli Lilly has posted another quarter of strong results driven by Mounjaro and Zepbound, lifting full-year guidance. Novo Nordisk trails in growth momentum as it works to regain share and assure investors of a clear long-term path. Foundayo’s launch adds a new dimension to Lilly’s portfolio.